Changes in negative symptoms and the risk of tardive dyskinesia: A longitudinal study

Acta Psychiatrica Scandinavica

Volumn 101, Issue 4, 2000, Pages 300-306

  Van Os, Jim ^a   Walsh, Elizabeth ^b   Van Horn, Elizabeth ^b   Tattan, Theresa ^b   Bale, Rob ^b   Thompson, Simon G ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b NONE

Author keywords

Negative symptoms; Psychosis; Schizophrenia; Tardive dyskinesia

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE; TARDIVE DYSKINESIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DYSKINESIA, DRUG-INDUCED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0034106687     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.2000.101004300.x     Document Type: Article

References (78)

1. Chiu H, Lau J, Lam L, Shum P. Association of negative symptoms with tardive dyskinesia in schizophrenic patients. Aust NZ J Psychiatry 1993;27:228-232.
2. Gold JM, Egan MF, Kirch DG et al. Tardive dyskinesia: neuropsychological, computerized lomographic, and psychiatric symptom findings. Biol Psychiatry 1991;30:587-599.
3. McCreadie RG, Barron ET, Winslow GS. The Nithsdale Schizophrenia survey: II. Abnormal movements. Br J Psychiatry 1982;140:587-590.
4. Waddington JL, Youssef HA, Dolphin C, Kinsella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Arch Gen Psychiatry 1987;44:907-912.
5. Bartzokis G, Hill MA, Altshuler L, Cummings JL, Wirshing W, May PR. Tardive dyskinesia in schizophrenic patients: correlation with negative symptoms. Psychiatry Res 1989;28:145-151.
6. Brown KW, White T. The association among negative symptoms, movement disorders, and frontal lobe psychological deficits in schizophrenic patients. Biol Psychiatry 1991;30:1182-1190.
7. Chen EY, Lam LC, Chen RY, Nguyen DG. Negative symptoms, neurological signs and neuropsychological impairments in 204 Hong Kong Chinese patients with schizophrenia. Br J Psychiatry 1996;168:227-233.
8. Fenton WS, Wyatt RJ, McGlashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 1994;51:643-650.
9. Guy W, Ban TA, Wilson WH. An international survey of tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:401-405.
10. Karson CN, Bracha HS, Powell A, Adams L. Dyskinetic movements, cognitive impairment, and negative symptoms in elderly neuropsychiatric patients. Am J Psychiatry 1990;147:1646-1649.
11. Liddle PF, Barnes TR, Speller J, Kibel D. Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia. Br J Psychiatry 1993;163:776-780.
12. Waddington JL, Youssee HA, Molloy AG, Km OB, Pugh MT. Association of intellectual impairment, negative symptoms, and aging with tardive dyskinesia: clinical and animal studies. J Clin Psychiatry 1985;46:29-33.
13. Van Os J, Gilvarry C, Bale R, Tattan T, Van Horn E, Thompson S. Tardive dyskinesia: are women really more at risk? Acta Psychiatr Scand 1998;99:288-293.
14. Yuen O, Caligiuri MP, Williams R, Dickson RA. Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures. Br J Psychiatry 1996;168:702-708.
15. Glassman RB. A neural systems theory of schizophrenia and tardive dyskinesia. Behav Sci 1976;21:274-288.
16. Owens DG, Johnstone EC. The disabilities of chronic schizophrenia: their nature and the factors contributing to their development. Br J Psychiatry 1980;136:384-395.
17. Owens DG, Johnstone EC, Frith CD. Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 1982;39:452-461.
18. McCreadie RG, Thara R, Kamath S et al. Abnormal movements in never-medicated Indian patients with schizophrenia. Br J Psychiatry 1996;168:221-226.
19. Wegner JT, Kane JM, Weinhold P, Woerner M, Kinon B, Lieberman J. Cognitive impairment in tardive dyskinesia. Psychiatr Res 1985;16:331-337.
20. Waddington JL, Youssef HA. Cognitive dysfunction in chronic schizophrenia followed prospectively over 10 years and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol Med 1996;26:681-688.
21. Davis EJ, Borde M, Sharma LN. Tardive dyskinesia and type II schizophrenia. Br J Psychiatry 1992;160:253-256.
22. Thomas P, McGuire R. Orofacial dyskinesia, cognitive function and medication. Br J Psychiatry 1986;149:216-220.
23. Barnes TR. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia. Psychiatr Dev 1987;5:301-319.
24. Waddington JL. Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. Int Rev Neurobiol 1989;31:297-353.
25. Van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R. Tardive dyskinesia: who is at risk? Acta Psychiatr Scand 1997;96:206-216.
26. Chakos MH, Alvir JM, Woerner MG et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996;53:313-319.
27. Caligiuri MP, Lacro JP, Rockwell E, McAdams LA, Jeste DV. Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry 1997;171:148-153.
28. UK700 Group. The outcome of intensive versus standard case management for severe psychotic illness: the UK700 case management trial. Lancet 1999;353:2185-2189.
29. UK700 Group. Comparison of intensive and standard case management for psychotic patients - rationale of the trial. Br J Psychiatry 1999;174:74-78.
30. UK700 Group. Predictors of quality of life in the severely mentally ill: study methodology and baseline analysis in the UK700 Case Management Trial. submitted manuscript 1998.
31. Spitzer RL, Endicott J, Robbins E. Research Diagnostic Criteria (RDC) for a Selected Group of Functional Psychoses, 3rd edn. New York: Biometrics Research Division, New York State Psychiatric Institute, 1978.
32. Guy W, Ban TA, Wilson WH. The prevalence of abnormal involuntary movements among chronic schizophrenics. Int Clin Psychopharmacol 1986;1:134-144.
33. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia (letter). Arch Gen Psychiatry 1982;39:486-487.
34. American Psychiatric Association. Diagnostic criteria from DSM-III-R. Washington, DC: American Psychiatric Association, 1987.
35. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991;48:764-770.
36. Jacobsson L, Von Knorring L, Mattsson B et al. The comprehensive psychopathological rating scale - CPRS in patients with schizophrenic syndromes. Inter-rater reliability and in relation to Martens' S-scale. Acta Psychiatr Scand 1978;Suppl. 271:39-44.
37. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 1989;1:960-5371.
38. Stata Corp. Stata statistical software: release 5. College Station, TX: Stata Corporation, 1997.
39. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993;50:723-733.
40. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993;19:303-315.
41. Van Harten PN, Matroos GE, Hoek HW, Kahn RS. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia. The Curacao Extrapyramidal Syndromes Study: I. Schizophr Res 1996;19:195-203.
42. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i:307-310.
43. Liddle PF. Schizophrenic syndromes, cognitive performance and neurological dysfunction. Psychol Med 1987;17:49-57.
44. Capleton RA. Cognitive function in schizophrenia: association with negative and positive symptoms. Psychol Rep 1996;78:123-128.
45. Stolar N, Berenbaum H, Banich MT, Barch D. Neuropsychological correlates of alogia and affective flattening in schizophrenia. Biol Psychiatry 1994;35:164-172.
46. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RS. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992;160:179-186.
47. Andreasen NC, Rezai K, Alliger R et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992;49:943-958.
48. Andreasen NC, Ehrhardt JC, Swayze VWd et al. Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities. Arch Gen Psychiatry 1990;47:35-44.
49. Van Os J, Fahy TA, Jones P et al. Increased intracerebral cerebrospinal fluid spaces predict unemployment and negative symptoms in psychotic illness. A prospective study. Br J Psychiatry 1995;166:750-758.
50. Chua SE, Wright IC, Poline JB et al. Grey matter correlates of syndromes in schizophrenia. A semi-automated analysis of structural magnetic resonance images. Br J Psychiatry 1997;170:406-410.
51. Levin S. Frontal lobe dysfunctions in schizophrenia II. Impairments of psychological and brain functions. J Psychiatr Res 1984;18:57-72.
52. Kirkpatrick B, Buchanan RW. The neural basis of the deficit syndrome of schizophrenia. J Nerv Ment Dis 1990;178:545-555.
53. Goldman Rakic PS, Selemon LD. Functional and anatomical aspects of prefrontal pathology in schizophrenia (see comments). Schizophr Bull 1997;23:437-458.
54. Waddington JL, E OC, Buckley P et al. Tardive dyskinesia in schizophrenia. Relationship to minor physical anomalies, frontal lobe dysfunction and cerebral structure on magnetic resonance imaging. Br J Psychiatry 1995;167:41-44.
55. Brown KW, White T, Palmer D. Movement disorders and psychological tests of frontal lobe function in schizophrenic patients. Psychol Med 1992;22:69-77.
56. Van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R. Tardive dyskinesia: who is at risk? Acta Psychiatr Scand 1997;96:206-216.
57. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8(Suppl 4):52S-56S.
58. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18:701-715.
59. Castle DJ, Murray RM. The neurodevelopmental basis of sex differences in schizophrenia (editorial). Psychol Med 1991;21:565-575.
60. Foerster A, Lewis S, Owen M, Murray R. Pre-morbid adjustment and personality in psychosis. Effects of sex and diagnosis. Br J Psychiatry 1991;158:171-176.
61. Navarro F, Van Os J, Jones P, Murray R. Explaining sex differences in course and outcome in the functional psychoses. Schizophr Res 1996;21:161-170.
62. Jeste DV, Lindamer LA, Evans J, Lacro JP. Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol Bull 1996;32:243-251.
63. Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp Commun Psychiatry 1994;45:38-42.
64. Sramek J, Roy S, Ahrens T, Pinanong P, Cutler NR, Pi E. Prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients. Hosp Commun Psychiatry 1991;42:590-592.
65. Chiu H, Shum P, Lau J, Lam L, Lee S. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Am J Psychiatry 1992;149:1081-1085.
66. Doongaji DR, Jeste DV, Jape NM et al. Tardive dyskinesia in India: a prevalence study. J Clin Psychopharmacol 1982;2:341-344.
67. Rosenblat R, Tang SW. Do Oriental psychiatric patients receive different dosages of psychotropic medication when compared with occidentals. Can J Psychiatry 1987;32:270-274.
68. Bond WS. Ethnicity and psychotropic drugs. Clin Pharm 1991;10:467-470.
69. Lin KM, Poland RE, Wan YJ, Smith MW, Lesser IM. The evolving science of pharmacogenetics: clinical and ethnic perspectives. Psychopharmacol Bull 1996;32:205-217.
70. Arthur H, Dahl ML, Siwers B, Sjoovist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995;15:211-216.
71. Benson PR. Drug information disclosed to patients prescribed antipsychotic medication. J Nerv Ment Dis 1984;172:642-653.
72. Citrome L, Levine J, Allingham B. Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol Bull 1996;32:321-326.
73. Segal SP, Bola JR, Watson MA. Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr Serv 1996;47:282-286.
74. Lawson WB. Clinical issues in the pharmacotherapy of African-Americans. Psychopharmacol Bull 1996;32:275-281.
75. Dunn J, Fahy TA. Police admissions to a psychiatric hospital. Demographic and clinical differences between ethnic groups (see comments). Br J Psychiatry 1990;156:373-378.
76. Price N, Glazer W, Morgenstern H. Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients. Am J Psychiatry 1985;142:1491-1492.
77. Shubsachs AP, Huws RW, Close AA, Larkin EP, Falvey J. Male Afro-Caribbean patients admitted to Rampton Hospital between 1977 and 1986 a control study. Med Sci Law 1995;35:336-346.
78. Strakowski SM, Shelton RC, Kolbrener ML. The effects of race and comorbidity on clinical diagnosis in patients with psychosis. J Clin Psychiatry 1993;54:96-102.